Scarica l'app Stockscreener
9.98
2.01%
-0.205
Dopo l'orario di chiusura:
9.95
-0.03
-0.30%
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
Aug Macro: Is Zevra Therapeutics Inc backed by strong institutional buying2026 Key Highlights & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Nio, Zevra Therapeutics, Vertex Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
A Look At Zevra Therapeutics (ZVRA) Valuation After Profitability And MIPLYFFA Commercial Progress - simplywall.st
Trading Systems Reacting to (ZVRA) Volatility - Stock Traders Daily
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
Trading Action: Should I set a stop loss on Zevra Therapeutics IncEarnings Beat & Daily Profit Focused Screening - baoquankhu1.vn
Zevra Therapeutics appoints Justin Renz as CFO - MSN
Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price Performance - Yahoo Finance
WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C - Zacks Investment Research
Zevra at Citizens Life Sciences: Strategic Growth and Expansion By Investing.com - Investing.com Canada
Zevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
ZVRA: MIPLYFFA drives rare disease growth with strong revenue, global expansion, and pipeline progress - TradingView
Can Zevra Therapeutics (ZVRA) Turn NPC Genetic Testing Access Into a Durable Rare-Disease Edge? - Yahoo Finance
Brokers Offer Predictions for ZVRA Q3 Earnings - MarketBeat
Zevra Therapeutics (ZVRA) Profit Swing To US$77.6m TTM Tests Rare Disease Bull Case - simplywall.st
Zevra Therapeutics Faces Partnership Hurdles That Could Delay Drug Development and Pressure Financing - TipRanks
Why Is Zevra Therapeutics Stock Trading Higher Today? - Bitget
Why Zevra Therapeutics stock zoomed 21% higher today - MSN
Why Zevra Therapeutics Stock Zoomed 21% Higher Today - Yahoo Finance
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap UpHere's What Happened - MarketBeat
Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model (NASDAQ:ZVRA) - Seeking Alpha
GeneDx Holdings Corp. to Launch Genetic Testing Program with Zevra Therapeutics, Inc. to Support Patients with Suspected Niemann-Pick Disease Type C - marketscreener.com
Zevra Therapeutics partners with GeneDx to launch genetic testing for NPC in U.S. - Traders Union
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C - Business Wire
Guggenheim raises Zevra Therapeutics stock price target to $23 By Investing.com - Investing.com Australia
US Premarket Movers: BioNTech, Kohl’s, Teladoc, Vertex, Zevra - Bloomberg.com
Guggenheim raises Zevra Therapeutics stock price target to $23 - Investing.com
Zevra Therapeutics price target raised to $23 from $22 at Guggenheim - TipRanks
Zevra Therapeutics Stock Pre-Market (+17%): Blowout Q4 Earnings & Revenue Beat - Trefis
Why Zevra Therapeutics Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket - Benzinga
Profit Swing, MIPLYFFA Uptake and New CFO Might Change The Case For Investing In Zevra Therapeutics (ZVRA) - simplywall.st
Zevra Therapeutics Stock Pre-Market (+17%): Reports Massive Q4 EPS Beat - Trefis
Zevra Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Zevra Therapeutics: Q4 Earnings Snapshot - theheraldreview.com
Earnings call transcript: Zevra Therapeutics Q4 2025 earnings beat forecasts By Investing.com - Investing.com South Africa
ZVRA Stock Soars On Upbeat Q4 Results, Optimism For EMA Approval Of Niemann-Pick Disease Treatment - Asianet Newsable
Earnings call transcript: Zevra Therapeutics Q4 2025 earnings beat forecasts - Investing.com
ZVRA Reports Strong Q4 Revenue and Strategic Growth Plans - GuruFocus
Zevra Therapeutics Q4 Earnings Call Highlights - MarketBeat
ZVRA: 2025 net income reached $83.2M on $106.5M revenue, led by MIPLYFFA's commercial success - TradingView
Zevra Therapeutics earnings beat by $0.14, revenue topped estimates - Investing.com Canada
Zevra Therapeutics Q4 2025 Earnings: $12.2M Net Income, Revenue Beats ForecastsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Zevra Therapeutics reports Q4 EPS 20c, consensus 5c - TipRanks
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Zevra Therapeutics: Fourth Quarter Earnings Overview - Bitget
Zevra Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ZEVRA THERAPEUTICS ($ZVRA) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
Zevra 2025 net income hits $83M on $106M revenue - National Today
Zevra Therapeutics Appoints Justin Renz as New CFO - TipRanks
ZVRA Exceeds Revenue Expectations and Expands Boston Headquarters - GuruFocus
Zevra Therapeutics (NASDAQ:ZVRA) Releases Earnings Results, Beats Estimates By $0.14 EPS - MarketBeat
Zevra Therapeutics Q4 Swings to Profit, Revenue Rises - marketscreener.com
Q4 2025 Zevra Therapeutics Inc Earnings Call Transcript - GuruFocus
Zevra Therapeutics beats FY 2025 revenue expectations - TradingView
Zevra Therapeutics Reports Q4 2025 Financial Results with 31% Revenue Growth and Announces Upcoming Conference Call - Quiver Quantitative
Zevra Therapeutics Q4 Earnings Report: What Investors Need to Know - Benzinga
From $105.5M net loss to $83.2M net income: Zevra 2025 results - Stock Titan
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):